|Articles|April 21, 2016
FDA's Breakthrough Designation is Working, Says Report
April 21, 2016.
Advertisement
The good news about FDA’s breakthrough drug initiative is that it actually appears to be accelerating clinical development of highly promising new therapies, according to recent analysis by Friends of Cancer Research (FOCR) .
Read Jill Wechsler's view in
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
3
Report: Richard Pazdur Out as Director of CDER
4
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
5
